Literature DB >> 21526706

Non-alcoholic fatty liver disease: a massive problem.

Christopher P Day1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21526706      PMCID： PMC5922746          DOI： 10.7861/clinmedicine.11-2-176

Source DB:  PubMed          Journal:  Clin Med (Lond)        ISSN： 1470-2118            Impact factor:   2.659


× No keyword cloud information.
  38 in total

1.  Transforming growth factor beta signaling in hepatocytes participates in steatohepatitis through regulation of cell death and lipid metabolism in mice.

Authors:  Ling Yang; Yoon Seok Roh; Jingyi Song; Bi Zhang; Cheng Liu; Rohit Loomba; Ekihiro Seki
Journal:  Hepatology       Date:  2013-12-18       Impact factor: 17.425

2.  Hepatic HAX-1 inactivation prevents metabolic diseases by enhancing mitochondrial activity and bile salt export.

Authors:  Fawzi Alogaili; Sivaprakasam Chinnarasu; Anja Jaeschke; Evangelia G Kranias; David Y Hui
Journal:  J Biol Chem       Date:  2020-02-20       Impact factor: 5.157

Review 3.  Novel insights into the mechanisms whereby isoflavones protect against fatty liver disease.

Authors:  Long-Xin Qiu; Tong Chen
Journal:  World J Gastroenterol       Date:  2015-01-28       Impact factor: 5.742

4.  Quantitative MRI for hepatic fat fraction and T2* measurement in pediatric patients with non-alcoholic fatty liver disease.

Authors:  Jie Deng; Mark H Fishbein; Cynthia K Rigsby; Gang Zhang; Samantha E Schoeneman; James S Donaldson
Journal:  Pediatr Radiol       Date:  2014-05-20

Review 5.  Herbal medicines and nonalcoholic fatty liver disease.

Authors:  Hong Yao; Yu-Jie Qiao; Ya-Li Zhao; Xu-Feng Tao; Li-Na Xu; Lian-Hong Yin; Yan Qi; Jin-Yong Peng
Journal:  World J Gastroenterol       Date:  2016-08-14       Impact factor: 5.742

Review 6.  Pediatric nonalcoholic fatty liver disease: a multidisciplinary approach.

Authors:  Anna Alisi; Ariel E Feldstein; Alberto Villani; Massimiliano Raponi; Valerio Nobili
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-01-17       Impact factor: 46.802

Review 7.  Pediatric non-alcoholic fatty liver disease: New insights and future directions.

Authors:  Pierluigi Marzuillo; Emanuele Miraglia Del Giudice; Nicola Santoro
Journal:  World J Hepatol       Date:  2014-04-27

8.  Low-density lipoprotein receptor-related protein-1 dysfunction synergizes with dietary cholesterol to accelerate steatohepatitis progression.

Authors:  Allyson N Hamlin; Sivaprakasam Chinnarasu; Yinyuan Ding; Xunde Xian; Joachim Herz; Anja Jaeschke; David Y Hui
Journal:  J Biol Chem       Date:  2018-05-11       Impact factor: 5.157

Review 9.  Resolvins, specialized proresolving lipid mediators, and their potential roles in metabolic diseases.

Authors:  Matthew Spite; Joan Clària; Charles N Serhan
Journal:  Cell Metab       Date:  2013-11-14       Impact factor: 27.287

10.  The glucagon-like peptide-1 receptor agonist Exendin 4 has a protective role in ischemic injury of lean and steatotic liver by inhibiting cell death and stimulating lipolysis.

Authors:  Nitika A Gupta; Vasantha L Kolachala; Rong Jiang; Carlos Abramowsky; Rene Romero; Nimita Fifadara; Frank Anania; Stuart Knechtle; Allan Kirk
Journal:  Am J Pathol       Date:  2012-09-05       Impact factor: 4.307
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.